Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

Published on Jun 1, 2019in Alzheimers & Dementia14.423
· DOI :10.1016/j.jalz.2019.01.015
Alberto Lleó43
Estimated H-index: 43
Daniel Alcolea23
Estimated H-index: 23
+ 25 AuthorsKaj Blennow123
Estimated H-index: 123
(University of Gothenburg)
Abstract Introduction Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined. Methods We included 467 subjects from the BIOMARKAPD study with at least two serial CSF samples. Diagnoses were subjective cognitive decline (n = 75), mild cognitive impairment (n = 128), and AD dementia (n = 110), and a group of cognitively unimpaired subjects (n = 154) were also included. We measured baseline and follow-up CSF levels of total tau (t-tau), phosphorylated tau (p-tau), YKL-40, and neurofilament light (NfL). Median CSF sampling interval was 2.1 years. Results CSF levels of t-tau, p-tau, NfL, and YKL-40 were 2% higher per each year of baseline age in controls (P  Discussion All four CSF biomarkers increase with age, but this effect deviates in AD for t-tau and p-tau.
  • References (44)
  • Citations (3)
📖 Papers frequently viewed together
90 Citations
8 Citations
23 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Katie E. Osborn (VUMC: Vanderbilt University Medical Center)H-Index: 5
#2Dandan Liu (VUMC: Vanderbilt University Medical Center)H-Index: 13
Last. Angela L. Jefferson (VUMC: Vanderbilt University Medical Center)H-Index: 37
view all 16 authors...
Abstract White matter hyperintensities (WMHs) are associated with poorer brain health, but their pathophysiological substrates remain elusive. To better understand the mechanistic underpinnings of WMHs among older adults, this study examined in vivo cerebrospinal fluid biomarkers of β-amyloid42 deposition (Aβ42), hyperphosphorylated tau pathology, neurodegeneration (total tau), and axonal injury (neurofilament light [NFL]) in relation to log-transformed WMHs volume. Participants free of clinical...
10 CitationsSource
#1Courtney L. Sutphen (WashU: Washington University in St. Louis)H-Index: 10
#2Lena McCue (WashU: Washington University in St. Louis)H-Index: 7
Last. AdniH-Index: 1
view all 8 authors...
Abstract Introduction Individuals in early stages of Alzheimer's disease are a targeted population for secondary prevention trials aimed at preserving normal cognition. Understanding within-person biomarker(s) change over time is critical for trial enrollment and design. Methods Longitudinal cerebrospinal fluid samples from the Alzheimer's Disease Neuroimaging Initiative were assayed for novel markers of neuronal/synaptic injury (visinin-like protein 1, Ng, and SNAP-25) and neuroinflammation (YK...
12 CitationsSource
#2Carla Gallo (UPCH: Cayetano Heredia University)H-Index: 20
#3Dimitrios Kapogiannis (NIH: National Institutes of Health)H-Index: 28
Last. Florence Thibaut (Paris V: Paris Descartes University)H-Index: 25
view all 4 authors...
AbstractIn the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer’s disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, bio...
63 CitationsSource
#1Sylvia VilleneuveH-Index: 17
#2Jacob W. Vogel (McGill University)H-Index: 11
Last. Judes Poirier (McGill University)H-Index: 8
view all 13 authors...
Importance Alzheimer disease (AD) develops during several decades. Presymptomatic individuals might be the best candidates for clinical trials, but their identification is challenging because they have no symptoms. Objective To assess whether a sporadic parental estimated years to symptom onset calculation could be used to identify information about amyloid-β (Aβ) levels in asymptomatic individuals with a parental history of AD dementia. Design, Setting, and Participants This cohort study analyz...
8 CitationsSource
#1Clifford R Jr. Jack (Mayo Clinic)H-Index: 137
#2David A. Bennett (Rush University)H-Index: 160
Last. Nina SilverbergH-Index: 13
view all 24 authors...
Abstract In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer's disease. Scientific progress in the interim led to an initiative by the National Institute on Aging and Alzheimer's Association to update and unify the 2011 guidelines. This unifying update is labeled a "research framework" because its intended use is for observational and interventional resear...
603 CitationsSource
#1Silvia Paola Caminiti (UniSR: Vita-Salute San Raffaele University)H-Index: 10
#2Tommaso BallariniH-Index: 5
Last. Elio ScarpiniH-Index: 57
view all 18 authors...
Abstract Background/aims In this multicentre study in clinical settings, we assessed the accuracy of optimized procedures for FDG-PET brain metabolism and CSF classifications in predicting or excluding the conversion to Alzheimer's disease (AD) dementia and non-AD dementias. Methods We included 80 MCI subjects with neurological and neuropsychological assessments, FDG-PET scan and CSF measures at entry, all with clinical follow-up. FDG-PET data were analysed with a validated voxel-based SPM metho...
17 CitationsSource
#1Babette L.R. Reijs (UM: Maastricht University)H-Index: 5
#2Inez H.G.B. Ramakers (UM: Maastricht University)H-Index: 18
Last. Pieter Jelle Visser (UM: Maastricht University)H-Index: 49
view all 16 authors...
Background: Performance on episodic, semantic, and working memory tests is impaired in Alzheimer disease (AD)-type dementia, but it is unclear which type of memory test is most strongly associated with early AD biomarkers in cerebrospinal fluid (CSF), and most useful for monitoring disease progression. Objective: To examine the association between amyloid-β 1-42 (Aβ42) and tau in CSF with performance on different memory domains at baseline, and how these CSF markers are related with memory decli...
9 CitationsSource
#1Babette L.R. Reijs (UM: Maastricht University)H-Index: 5
#2Inez H.G.B. Ramakers (UM: Maastricht University)H-Index: 18
Last. Pieter Jelle Visser (UM: Maastricht University)H-Index: 49
view all 14 authors...
Background: Impaired olfactory function is an early characteristic of Alzheimer's disease (AD), but it remains unclear if odor identification also relates to early markers of AD in cerebrospinal fluid (CSF). Objective: To investigate the association between odor identification and amyloid-β 1-42 (Aβ42) and total tau (t-Tau) concentrations in CSF. In addition, to examine the relation between odor identification and cognitive function at baseline and at follow-up, and whether these associations ar...
8 CitationsSource
#1Daniel AlcoleaH-Index: 23
#2Eduard VilaplanaH-Index: 9
Last. Alberto LleóH-Index: 43
view all 18 authors...
Objective: To analyze the clinical utility of 3 CSF biomarkers and their structural imaging correlates in a large cohort of patients with different dementia and parkinsonian syndromes within the spectrum of frontotemporal lobar degeneration (FTLD). Methods: We analyzed 3 CSF biomarkers (YKL-40, soluble β fragment of amyloid precursor protein [sAPPβ], neurofilament light [NfL]) and core Alzheimer disease (AD) biomarkers (β-amyloid 1-42 , total tau, phosphorylated tau) in patients with FTLD-relate...
33 CitationsSource
#1Marta Querol-Vilaseca (Autonomous University of Barcelona)H-Index: 3
#2Martí Colom-Cadena (Autonomous University of Barcelona)H-Index: 8
Last. Alberto Lleó (Autonomous University of Barcelona)H-Index: 43
view all 8 authors...
Background The innate immune system is known to be involved early in the pathogenesis of Alzheimer’s disease (AD) and other neurodegenerative disorders. The inflammatory response in the central nervous system can be measured postmortem or through a series of inflammatory mediator surrogates. YKL-40 (also named Chitinase-3-like I) has been frequently investigated in body fluids as a surrogate marker of neuroinflammation in AD and other neurological disorders. However, the expression pattern of YK...
24 CitationsSource
Cited By3
#1Brian A. Gordon (WashU: Washington University in St. Louis)H-Index: 21
Neurofilaments are proteins selectively expressed in the cytoskeleton of neurons, and increased levels are a marker of damage. Elevated neurofilament levels can serve as a marker of ongoing disease activity as well as a tool to measure response to therapeutic intervention. The potential utility of neurofilaments has drastically increased as recent advances have made it possible to measure levels in both the cerebrospinal fluid and blood. There is mounting evidence that neurofilament light chain ...
#1Giulia Cisbani (U of T: University of Toronto)H-Index: 1
#2Alex Koppel (CAMH: Centre for Addiction and Mental Health)
Last. Richard P. Bazinet (U of T: University of Toronto)H-Index: 41
view all 6 authors...
Abstract Neuroinflammation is thought to be important in the progression of Alzheimer’s disease (AD). To evaluate cerebral inflammation using positron emission tomography (PET) imaging with a radioligand that target TSPO, a translocator protein upregulated in microglia and macrophages during inflammation, can be used in conjunction with positron emission tomography (PET) imaging. In AD patients, neuroinflammation is up-regulated compared to both healthy volunteers as well as to subjects with mil...
#1Andrew J. Aschenbrenner (WashU: Washington University in St. Louis)H-Index: 10
#2Brian A. Gordon (WashU: Washington University in St. Louis)H-Index: 21
Last. Jason Hassenstab (WashU: Washington University in St. Louis)H-Index: 20
view all 7 authors...
BACKGROUND: Cerebrospinal fluid tau and neurofilament light (NfL) are two biomarkers of neurodegeneration in Alzheimer's disease. Previous reports have shown that the influence of tau on cognitive decline depends on levels of amyloid burden whereas NfL predicts decline independently of amyloid. Most studies use a global cognitive composite as the primary outcome, and it is unknown if critical cognitive domain scores are similarly sensitive to rates of decline due to neurodegeneration. OBJECTIVE:...
#1Gregory S. Day (WashU: Washington University in St. Louis)H-Index: 9
#2Tracy Rappai (WashU: Washington University in St. Louis)
Last. John C. Morris (WashU: Washington University in St. Louis)H-Index: 153
view all 4 authors...
#1Kirsten E. J. Wesenhagen (VU: VU University Amsterdam)
#2Charlotte E. Teunissen (VU: VU University Amsterdam)H-Index: 48
Last. Betty M. Tijms (VU: VU University Amsterdam)H-Index: 17
view all 4 authors...
AbstractAlzheimer’s disease (AD) is the most common cause of dementia and is characterized by aggregation of amyloid and tau proteins in the brain. Results from genetic studies suggest that the pat...
#1Michael Khalil (Medical University of Graz)H-Index: 27
#2Lukas Pirpamer (Medical University of Graz)H-Index: 12
Last. Franz Fazekas (Medical University of Graz)H-Index: 87
view all 12 authors...
Neurofilament light (NfL) protein is a marker of neuro-axonal damage and can be measured not only in cerebrospinal fluid but also in serum, which allows for repeated assessments. There is still limited knowledge regarding the association of serum NfL (sNfL) with age and subclinical morphologic brain changes and their dynamics in the normal population. We measured sNfL by a single molecule array (Simoa) assay in 335 individuals participating in a population-based cohort study and after a mean fol...
#1Katheryn A.Q. Cousins (UPenn: University of Pennsylvania)H-Index: 3
#2David J. Irwin (UPenn: University of Pennsylvania)H-Index: 33
Last. Jeffrey S. Phillips (UPenn: University of Pennsylvania)H-Index: 9
view all 10 authors...
Under the ATN framework, cerebrospinal fluid analytes provide evidence of the presence or absence of Alzheimer9s disease pathological hallmarks: amyloid plaques (A), phosphorylated tau (T), and accompanying neurodegeneration (N). Still, differences in cerebrospinal fluid levels across amnestic and non-amnestic variants or due to co-occurring pathologies might lead to misdiagnoses. We assess the diagnostic accuracy of cerebrospinal fluid markers for amyloid, tau, and neurodegeneration in an autop...
Alzheimer’s disease (AD) is the most common neurodegenerative disease and its diagnosis has classically been based on clinical symptoms. Recently, a biological rather than a syndromic definition of...
#1Rita Khoury (Saint George Hospital)
#2Elias Ghossoub (AUB: American University of Beirut)H-Index: 1
Abstract In 2018, there was a recent shift towards a biological definition of Alzheimer's disease (AD), based on biomarkers measured in vivo even before the onset of clinical dementia symptoms. No single biomarker can by itself accurately diagnose AD. A combination of biomarkers assessed through imaging and cerebrospinal fluid (CSF) yields better diagnostic accuracy. Although amyloid PET imaging and CSF levels of amyloid and tau deposits are increasingly used in AD clinical trials to increase di...